Upadacitinib improves health-related QoL in difficult-to-treat RA

Among those with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs, upadacitinib, in doses of either 15 mg or 30 mg, increased quality of life and resulted in more patients reaching clinically meaningful improvements, according to data published in Arthritis Research & Therapy.“Rheumatoid arthritis is a chronic disease associated with reduced

Read the full article here

Related Articles